Search Here

Trimel Pharmaceuticals Corporation announced that its sexual disorder drug was effective in treating women during the second mid-stage study. The drug, Tefina, which is administered via the nasal passageway, was capable of increasing the average number of orgasms experienced by women with an orgasmic disorder.

"Female Orgasmic Disorder is the second most prevalent sexual disorder affecting women. Approximately one in five women report difficulty with orgasm and one quarter of these show marked distress, a key criterion in a clinical diagnosis," said Dr. Sheryl Kingsberg, the U.S. principal investigator for the Tefina(TM) Phase II clinical trial, chief of behavioral medicine at University Hospitals Case Medical Center and professor of reproductive biology and psychiatry at Case Western Reserve University in Cleveland, OH.

In the study, the researchers had recruited 253 patients who were divided into a drug group and a placebo group. Over the time span of 84 days, the participants received three varying doses of Tefina that were administered in the home setting. The team found that the lowest dose of the drug, at 0.6mg, was effective in treating female orgasmic disorder known as anorgasmia. Women with the condition experience delays, absence or reduced intensity in their orgasms.

Pre- and post-menopausal women who were treated experienced more orgasms than the women from the placebo group. They also reported higher levels of sexual function and satisfaction with lower levels of distress. The researchers did not provide information about the effects of the other two doses of Tefina. If the drug continues to be successful in future trials, it could help improve couple's sex lives. Women with anorgasmia are often treated with hormone tablets and patches.

"Currently, there are no approved pharmacological treatment options, leaving an unmet need that Tefina(TM) hopes to remedy," Dr. Kingsberg said according to the Wall Street Journal. "These results mark an important milestone in the development of Tefina(TM). They provide further evidence that Tefina(TM) could represent an important treatment option for the many women who suffer from this disorder. On behalf of Trimel and its various stakeholders, I am extremely excited about this positive outcome and look forward to advancing this product towards commercialization."